Automated Process Control for the Development Laboratory - - BioPharm International


Automated Process Control for the Development Laboratory

BioPharm International
Volume 19, Issue 3


Figure 2. Fermentation lab
In 1990 the Process Science group at this company had a typical fermentation lab, with an eclectic collection of instrumentation. Scientists collected data and managed recipe development for new drugs in the tried-and-true, old-fashioned way. To monitor the development process, they walked around the lab recording data on a clipboard from each instrument, and then manually entered all the data into a spreadsheet. Based on their analysis of this aggregated data, they returned to each controller to adjust the recipe process by hand, in order to optimize the recipe for maximum effectiveness and best yield.

A few years ago, the company acquired the pharmaceutical assets of another company. With this acquisition they got a mixed set of expensive instrumentation. Adding these instruments to the lab resulted in a wide variety of equipment of assorted age and from various vendors. They had reactor vessels connected to either B. Braun Biostats or New Brunswick Scientific BioFlos. They had probes, pumps, valves, meters, gas mixers, and scales. Just about every make and model was represented. Each vendor's instrument had its own proprietary interface and few of the instruments talked to the others. Each biocontroller operated in isolation. The data aggregation, integration, and analysis became even more cumbersome.

This scenario of manual methods for instrument monitoring, control, and data management is still the status quo in many R&D, process development labs, and pilot plants today. They are "tried and true," and many businesses depend on established, "trusted" procedures rather than risk introducing change. On the other hand, plenty of lab directors would welcome automation, as would the scientists and technicians who do the daily tasks of managing cell culture or fermentation experiments. Often, they believe that manual process control and data collection are the only alternatives available, given the equipment they have to use. Most comprehensive automation systems are large-scale, expensive systems with required hardware (such as PLCs) and fully customized software. These systems are just not practical in the process development lab or pilot plant, where automation rightfully takes a back seat to experimentation, innovation and cost-savings.

This status quo of manual process control and data management is partly dictated by the instrumentation. Instrument manufacturers focus on excellence in function, accuracy, and speed of their devices. They are typically less concerned with acting as part of a larger whole, sharing and communicating with other instruments in "the big picture." The result is islands of data: isolated measurements and analyses, and isolated subsystems like scattered puzzle pieces. Instrument manufacturers have specific expertise, and concentrate more on perfecting their own island, and less on building bridges. A particular instrument could be a piece in many different puzzles, serving a variety of larger processes. It is a challenge to be a team player in those many different systems.


Table 1. Opportunity Costs
The Lab Director of Process Science at the company recognized that the costs of managing the isolated islands of data and trying to bridge the gaps between them were hurting his biopharmaceutical business. He foresaw opportunity costs growing steeply, because his products and processes were becoming increasingly complex, patent competition more intense, and time-to-market more critical. For example, Table 1 shows three examples of drugs and their average daily revenue. You can see a large lost opportunity cost for every additional day that was spent in its development.

The Process Science Lab Director was not going to replace or upgrade all the instrumentation in order to achieve a unified system. After all, that would also be a waste of good equipment. His strategy was to bring old devices, new devices, and future unknown devices under one umbrella.

The Process Science group had been taking small steps toward automation, contracting for custom software that did crude control and data collection for individual reactors, and trying software applications supplied by the biocontroller vendors. The limitations of these led to the decision to put a comprehensive, automated data management and process control software system into place.

blog comments powered by Disqus



FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here